Art
J-GLOBAL ID:201702248518977451   Reference number:17A0004570

EGFR遺伝子変異陽性肺腺癌に対しEGFR-TKI治療後,気管支鏡下再生検を施行し組織診陰性であった3症例

Author (7):
Material:
Volume: 56  Issue:Page: 219-226(J-STAGE)  Publication year: 2016 
JST Material Number: U0408A  ISSN: 1348-9992  Document type: Article
Article type: 原著論文  Country of issue: Japan (JPN)  Language: JAPANESE (JA)
Thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
Semi thesaurus term:
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
   To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0004570&from=J-GLOBAL&jstjournalNo=U0408A") }}
JST classification (2):
JST classification
Category name(code) classified by JST.
Tumors(=neoplasms)of respiratory system  ,  Clinical application of antitumor(=antineoplastic)drugs 
Reference (7):
  • 1. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19: 2240-2247.
  • 2. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372: 1689-1699.
  • 3. Jekunen AP. Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol. 2015; 2015: 809835.
  • 4. Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013; 119: 4325-4332.
  • 5. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565
more...

Return to Previous Page